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One year into the coronavirus disease 2019 (COVID-19) epi-
demic, data regarding a more detailed risk profile and treatment
aspects of patients with immune-mediated kidney diseases and
anti-neutrophil cytoplasmic antibody–associated vasculitis
(AAV) have remained scarce. The International Registry of
COVID infection in glomerulonephritis reported 40 patients
with primary glomerulonephritis including AAV. Compared
with 80 hospitalized controls, mortality and acute kidney rates
were significantly higher in patients with glomerulonephritis
[1]. A UK and Ireland Vasculitis Society analysis of 65 vasculitis
patients found associations between comorbid respiratory dis-
ease and prescription of glucocorticoids with severe outcomes
(Supplementary data, Table S1) [2].
Some treatment data are available from rheumatology regis-
try studies. Immunosuppression and outcomes of 694 COVID-
19 patients with inflammatory rheumatic and musculoskeletal
diseases was reported from France. Older age, comorbidities in-
cluding chronic kidney disease (CKD) and the use of glucocor-
ticoids 10 mg/day or equivalent (prednisone) or rituximab
were associated with COVID-19 severity [3]. In a recent publi-
cation from the COVID-19 Global Rheumatology Alliance
of 3729 severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2)-infected patients, older age, male sex, CKD and
other comorbidities were associated with COVID-19-related
death, which occurred in 10.5%. Disease-specific factors such
as moderate/high disease activity, a diagnosis of vasculitis
and drugs such as rituximab were associated with mortality
(Supplementary data, Table S1) [4]. In neither of these studies
were differences between induction or maintenance treatment
reported. In a real-life setting, rituximab has frequently been
postponed during the pandemic to mitigate the risk of severe
SARS-CoV-2 infections. Twenty-one of 206 studied patients
with AAV had their rituximab maintenance treatment post-
poned. Relapses or flares of disease occurred in 12 of these
cases. The disruption of care was highlighted, as this may have
contributed to delayed relapse diagnosis [5]. These recent find-
ings underline that rituximab-treated patients are at risk of de-
veloping severe COVID-19, but effective treatment needs to be
maintained to reduce the risk of disease relapse in AAV.
R I T U X I M A B A N D I N D U C T I O N /
M A I N T E N A N C E T H E R A P Y
The impact of the pandemic has varied between countries and
regions. Risk profiles of patient groups and therapies have
emerged and become more apparent with cases of COVID-19
prior to and after AAV diagnosis, and in some cases concur-
rently. How to best treat new or relapsing AAV needs consider-
ation since the pandemic is not over. Glucocorticoid therapy as
induction should preferably be dosed in the range of 0.5 mg/kg/
day or equivalent (prednisone) and reduced to <10 mg/day as
soon as possible. Rituximab may also constitute an additional
risk. However, it is essential to not delay effective treatment of
new AAV and rapidly progressive glomerulonephritis and to
treat relapses adequately. Cyclophosphamide or mycophenola-
temofetil induction, or even methotrexate, depending on kidney
function, may be alternatives [6].
Whether patients with rituximab maintenance therapy
without or on a low dose of corticosteroids have lower
COVID-19-associated risks needs to be studied further.
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Concurrently, rituximab has been discussed as a potential
therapy in severe COVID-19. Some patients produce antibod-
ies that functionally block the production of interferon-stimu-
lated gene-expressing cells, which are associated with milder
disease forms [7].
R I T U X I M A B A N D C O V I D - 1 9 V A C C I N E S
COVID-19 vaccines are the most promising approach to rein in
the current pandemic. It is nevertheless possible that COVID-
19 vaccine efficacy and response rates are lower in patients with
immunosuppressive therapy and CKD than in the pivotal stud-
ies published so far [8]. There may be a concern of vaccines pro-
voking disease relapses, but immunization against influenza
does not appear to increase the relapse rate in patients with
AAV [9]. The use of anti-CD20 monoclonal antibodies such as
rituximab is of particular concern, as it induces rapid and pro-
longed B-cell depletion, abrogating humoral immunity and
thereby vaccine response. In rheumatoid arthritis (RA) patients,
influenza vaccination 1–2 months after rituximab did not ex-
hibit an immunoglobulin M (IgM) or IgG response compared
with a measurable IgG response in rituximab-treated RA sub-
jects 6–10 months before vaccination [10]. Similar concerns
have been raised by the haematology and neurology communi-
ties, leading to suggestions for an optimal time window to vacci-
nate individuals treated with B-cell-depleting therapies that will
allow immunity to new infections [11].
‘Vaccine readiness’ needs to take two scenarios into account:
induction of remission in patients presenting with a new diag-
nosis or relapse and maintenance of remission. In patients with
a new diagnosis or relapse of AAV, an alternative therapeutic
approach to rituximab may be chosen to achieve remission.
During the maintenance phase, we suggest that the time win-
dow before SARS-CoV-2 vaccine administration should be a
minimum of 6 months after rituximab. AAV patients have been
shown to have a considerably longer time to B-cell repopulation
after rituximab when compared with RA and other connective
tissues diseases [12]. In addition, previous investigations have
indicated that the production of neutralizing antibodies and
specific vaccination responses are blunted until B cells repopu-
late (Figure 1), which may argue for measurements of B cells be-
fore vaccines are scheduled, as it may vary between individuals.
Again, the time frame after the last vaccine dose should be
4 weeks before B-cell-depletion therapy is again given. We also
suggest that antibody response and potentially cellular immu-
nity should be monitored regularly with an appropriate assay
and that booster doses should be considered if serology
responses decline or SARS-CoV-2 variants of concern with re-
duced effectiveness for current vaccines emerge.
Vaccine ‘rollout’ to this vulnerable patient group has been
slow in a number of countries, including those of the European
Union. Most will tailor maintenance treatment and likely delay
additional doses of rituximab. Again, temporary application of
less-effective maintenance agents (e.g. azathioprine) might be
considered, with a potential switch to rituximab once an appro-
priate immune response is ensured. Finally, little is known
about SARS-CoV-2 immunity in AAV patients after having ex-
perienced COVID-19, and even less if this will be affected by
rituximab. Repeated serology monitoring and a readiness to ad-
minister booster doses may be a reasonable approach.
F U N D I N G

































FIGURE 1: Rituximab therapy blunts humoral vaccine response by depleting CD20, which is expressed from the early pre-B-cell stage to the
mature B-cell stage (including memory B cells). Effects on T-cell immunity are unclear, but remain likely unchanged following anti-CD20-de-
pleting therapy. The most promising vaccine platforms include messenger RNA vaccines, replication-defective viral vector vaccines, purified
protein vaccines and inactivated virus vaccines. The efficacy estimates are either published Phase 3 trial results or based on press releases.
Notably, most COVID-19 vaccine candidates have been tested in a ‘healthy’ population and patients with autoimmune diseases and receiving
immunosuppressive measures have been excluded from major trials.
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